Mayo Clinic
This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone resorption in elderly adults.
To the researchers' knowledge, there are no published studies utilizing Fisetin in alteration of frailty markers. Several studies involve use of Fisetin for its anti-oxidative and anti-apoptotic effects in animal models. Fisetin may reduce oxidative stress, alleviate hyperglycemia, and improve kidney function. No one has evaluated the biologic markers of inflammation and frailty in older adults. The researchers plan to evaluate markers of frailty and markers of inflammation, insulin resistance, and bone resorption while maintaining bone formation in older adults.
Inclusion Criteria • Age ≥ 70 years Exclusion Criteria * Unable or unwilling to give informed consent * Pregnant * Body weight \>150 kg or body mass index (BMI) \> 50 * QTc\>450 msec * Total bilirubin \>2X upper limit of normal * Inability to tolerate oral medication * Abnormality in any of the screening laboratory studies (see below) * Human immunodeficiency virus infection * Known active hepatitis B or C infection * Invasive fungal or viral infection * Known hypersensitivity or allergy to fisetin * Uncontrolled pleural/pericardial effusions or ascites * New/active invasive cancer except n…
Flavonoid Family
Placebo
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.